AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017
Feb 7, 2017
29864_dirs_2017-02-07_d1e1853a-fe96-4ac2-96a1-d558c9ebc82b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-02-03
Reporting Person: LEIDEN JEFFREY M (Director, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-02-03 | Common Stock | A | 17895 | $0.01 | Acquired | 279982 | Direct |
| 2017-02-03 | Common Stock | A | 50567 | $0.00 | Acquired | 330549 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-03 | Stock Option (Right to Buy) | $86.52 | A | 103550 | Acquired | 2027-02-02 | Common Stock (103550) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 440 | Indirect |
Footnotes
F1: Represents earned performance shares with respect to a performance stock unit award granted on 2/02/2016 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2017. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
F2: Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020.
F3: The option vests in 16 quarterly installments from 02/03/2017.